Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of BIBW 2992 (Afatinib) in Healthy Male Volunteers
NCT02171767Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2009
- Primary completion
- Oct 2009
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum measured concentration of the analyte in plasma, Area under the concentration-time curve from 0 to the last quantifiable data point and 1 more. Started Aug 2009; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02171767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171767.